FGF21 and metabolic dysfunction-associated steatohepatitis: In phase 2b trials, treatment of nonalcoholic steatohepatitis (NASH) with pegozafermin (a glycopegylated fibroblast growth factor 21 analog) led to improvements in fibrosis.